WALTHAM, Mass., Sept. 18, 2017 /PRNewswire/ -- Alere Inc. (NYSE: ALR), a global leader in rapid diagnostics, has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR-B). The dividend is payable on October 16, 2017 to holders of record of Series B stock at the close of business on October 2, 2017.
Such payment will cover the amount of all dividends accrued from July 1, 2017 through September 30, 2017.
Abbott Laboratories has made an offer to purchase for cash all outstanding shares of Series B Convertible Perpetual Preferred Stock at $402.00 per share, plus accrued but unpaid dividends to, but not including, the settlement date of the offer. For more details, see the Tender Offer Statement on Schedule TO (together with the exhibits and amendments thereto) filed by Abbott with the Securities and Exchange Commission on July 17, 2017. As set forth in the Solicitation/Recommendation Statement filed by Alere with the Securities and Exchange Commission on Schedule 14D-9 on July 21, 2017, Alere makes no recommendation, expresses no opinion and remains neutral regarding whether holders of shares of Series B Convertible Perpetual Preferred Stock should participate in this offer.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can identify these statements by forward-looking words such as "may," "could," "should," "would," "intend," "will," "expect," "anticipate," "believe," "estimate," "continue" or similar words. A number of important factors could cause actual results of Alere and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the risk factors detailed in Part I, Item 1A, "Risk Factors," of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 (as filed with the Securities and Exchange Commission on June 5, 2017) and other risk factors identified herein or from time to time in our periodic filings with the SEC. Readers should carefully review these risk factors, and should not place undue reliance on our forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this communication. We undertake no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.
Alere believes that when diagnosing and monitoring health conditions, Knowing now matters™. Alere delivers on this vision by providing reliable and actionable information through rapid diagnostic tests, enhancing clinical and economic health outcomes globally. Headquartered in Waltham, Mass., Alere focuses on rapid diagnostics for infectious disease, cardiometabolic disease and toxicology. For more information on Alere, please visit www.alere.com.
SOURCE Alere Inc.